The US Food and Drug Administration will be evaluating whether proposed new opioid analgesics provide any advantages over existing pain therapeutics and could make it a requirement for approval. The agency also will be considering if a proposed product has any comparative safety and efficacy data.
The agency issued draft guidance on 20 June describing the benefit-risk assessment it uses in evaluating applications for opioid analgesic...






